Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Finished Goods: 2022-2025

Historic Finished Goods for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to $295,809.

  • InMed Pharmaceuticals' Finished Goods fell 68.10% to $295,809 in Q3 2025 from the same period last year, while for Sep 2025 it was $295,809, marking a year-over-year decrease of 68.10%. This contributed to the annual value of $676,178 for FY2025, which is 19.58% down from last year.
  • InMed Pharmaceuticals' Finished Goods amounted to $295,809 in Q3 2025, which was down 56.25% from $676,178 recorded in Q2 2025.
  • InMed Pharmaceuticals' Finished Goods' 5-year high stood at $927,182 during Q3 2024, with a 5-year trough of $231,956 in Q1 2025.
  • Over the past 3 years, InMed Pharmaceuticals' median Finished Goods value was $675,164 (recorded in 2024), while the average stood at $626,346.
  • Per our database at Business Quant, InMed Pharmaceuticals' Finished Goods surged by 88.73% in 2023 and then plummeted by 68.10% in 2025.
  • InMed Pharmaceuticals' Finished Goods (Quarterly) stood at $605,956 in 2022, then fell by 7.94% to $557,859 in 2023, then climbed by 21.03% to $675,164 in 2024, then crashed by 68.10% to $295,809 in 2025.
  • Its last three reported values are $295,809 in Q3 2025, $676,178 for Q2 2025, and $231,956 during Q1 2025.